Conduit Pharmaceuticals to Map Drug Development with AI

January 28, 2025

DENVER, Colo., Jan 28, 2025 (247marketnews.com)- Conduit Pharmaceuticals (NASDAQ: CDT) announced the successful completion of the first phase of its strategic collaboration with Sarborg Limited, marking a pivotal step in its commitment to revolutionizing drug development through advanced artificial intelligence (AI) and cybernetics. This collaboration, initiated in December 2024, aims to integrate AI-driven processes into Conduit’s operations to accelerate drug discovery, streamline drug repurposing, optimize solid-form identification, and enhance clinical trial monitoring. These advancements are expected to significantly shorten drug development timelines, reduce costs, and improve the predictability of successful outcomes.

The collaboration has already seen the completion of key milestones, including Teach-in Sessions and Proprietary Inputs Validation, tailored specifically to Conduit’s portfolio of proprietary assets. These early workstreams will help integrate AI technologies to increase the efficiency of advancing assets like AZD1656, AZD5904, AZD5658, CDT1656, and AZD1656 cocrystals, with a focus on its upcoming Phase 2 clinical trials in autoimmune disorders. By applying AI to these critical areas, Conduit aims to drive faster, more cost-effective development processes, which could ultimately lead to more efficient delivery of therapies to patients.

“Through our collaboration with Sarborg, we are poised to minimize the resource-intensive steps in drug development, opening the door to new therapeutic opportunities that were previously constrained by traditional methods,” said the company. As Conduit continues to build on the success of this collaboration, the company is setting itself up to be a leader in applying AI to the pharmaceutical sector. The goal is clear: to create a future where drug development is faster, more affordable, and more innovative, driven by cutting-edge technologies like AI and cybernetics.

Conduit’s work with Sarborg is just the beginning of its journey to lead the charge in the next generation of drug development, one that maximizes the potential of advanced technology to improve patient outcomes across a range of therapeutic areas.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CDT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.